Press Room

Press Clipping / Nov 16, 2018

Employee focus on ethical issues keeps firms on a righteous path

Irish Examiner, November 16, 2018

This year, a further seven companies were recertified to the standard: Boots Retail, CRH, Deloitte, ESB, Gas Networks Ireland, Intel and KBC Bank Ireland.

In all, 33 companies have now achieved the BWR mark, which is hosted by Business in the Community Ireland (BITCI), which assesses applicant companies’ sustainability and corporate social responsibility commitments.

Significantly, this year’s event also saw 43 companies pledge to cut their carbon emissions between now and 2030. The signatories are in retail, manufacturing, agri-food, professional services, banks, transport and ICT.

It is becoming increasingly important for Irish companies to measure and prove their commitments to sustainability, the environment and engagement with employees and local communities. And nudging those commitments on are their existing and prospective new employees, who are becoming increasingly insistent on working in a caring workplace.

“We look at companies’ activities across the board, across their various management practices,” said BITCI’s CEO, Tomás Sercovich.

The companies speak very highly of the mark, and that is because we are very thorough about the audit process. We have 22 auditors who conduct best-in-class audits. Companies find it useful to have a third party come in to observe their policies in practice

“The truth is that companies are also very good at using this mark as a way of differentiating themselves in an increasingly complicated employment market. I know there are people working in life sciences who changing jobs, some just crossing the road to take work with a competitor.” In many cases, the employees are citing ethical grounds when changing jobs. Mr Sercovich said many new graduates are now asking companies policy questions about plastic, recycling and carbon footprint at interviews.

In the case of Cork Harbour industries, would-be employees are asking about any impacts on the harbour. In retail, companies are also becoming more attuned to the ethical antennae of their employees. One Dutch supermarket recently introduced a plastic-free aisle.

“Millennials in particular are looking to work with companies who have deep commitments across a range of issues,” Mr Sercovich said. “They’re digging deep with their questions. They won’t accept a box-ticking exercise, they want companies with real values integrated into their business models and their everyday activities.” This is where BITCI’s support is so important to companies. Going for the BWR mark is not without its risks. Attaining the mark is really demanding, so there is a very real risk of being embarrassed by falling short. Several recipients said they were relieved as well as delighted.

“We’re extremely proud to have achieved the Business Working Responsibly mark,” said Maarten Schuurman, managing director, Heineken Ireland. “It’s wonderful to see the emphasis we place on sustainability and responsibility across all aspects of our business recognised and benchmarked independently.

“The mark serves as a clear signal to our stakeholders and our customers and consumers that we are listening; that we know sustainability matters to them as much as it does to us; and that we are working every day to make Heineken Ireland a truly green brewer.” Kathryn D’Arcy, Heineken’s director of corporate affairs, added: “Our commitment to sustainability and the environment is a long journey. We need to make decisions today that will have a positive impact on the world for the people who are coming behind us.

“Heineken has built up a proud heritage over 160 years. We’re producers of premium beers and ciders. Using only quality sustainable ingredients is at the heart of what we do. The Business Working Responsibly mark is a useful part of our journey. We want our heritage and commitments to be around for another 160 years.”

Meanwhile, Hovione in Ringaskiddy is another of this year’s four new companies to achieve the Business Working Responsibly mark. It is also one of those to have signed up to BITCI’s dedicated pledge to significantly reduce their carbon emissions.

“The award fits in well with our commitment to operating sustainably,” said Paul Downing, general manager of Hovione. “We have done a lot of work in managing our carbon footprint.

Achieving the Business Working Responsibly mark is important to us, and we will be celebrating the award with our staff and the on-site team dedicated to managing this for us. The mark is also important in terms of attracting and retaining talented employees

Dr. Downing said it is increasingly a feature for job candidates to ask about companies’ commitments to the environment, their employees and their local community. Membership of BITCI is one useful measure for demonstrating Hovione’s commitments.

“People joining the company frequently ask questions about our corporate social responsibility programme,” said Mr Downing. “The Business Working Responsibly mark is a very useful measure of our environmental and community commitments.”

Hovione is also the first chemical or pharmaceutical company to become B Corp certified. B Corp is a global community of companies committed to collectively solving social and environmental problems.

 

Read the entire article

 

 

Also in the Press Room

See All

International Pharmaceutical Industry journal speaks with Márcio Temtem, VP Strategic Business Management at Hovione, about how the company’s deep-rooted expertise in complex chemistry differentiates it within the CDMO landscape, enables seamless integration from drug substance to drug product, and supports partners in accelerating the development of high-potency APIs, advanced formulations, and next-generation therapeutic modalities. How does your complex chemistry expertise differentiate you from other CDMOs and how does it translate into helping partners accelerate the development of increasingly sophisticated APIs and formulations? Hovione has been associated with complex chemistry since its genesis. The company started by developing very tough chemistry on corticosteroids and antibiotics, which was an expertise that in the 90s we transferred into the contract manufacturing business.  Since then, Hovione has been exploring chemistry and its complexity in contract manufacturing through several angles. One is the ability to have assets across the globe and at different scales that allow the company to address various client needs. Another example of being able to tackle the complexity is having assets that can address molecules with different levels of potency. High potency is something that we offer in many of our facilities. Over the years, we have also tackled chemistries that are difficult to manage, like hydrogenations and cryogenic reactions. All these are part of a menu that we offer into the services. Hovione is always attentive to the client’s needs. The next step after chemistry, which typically tends to be particle engineering, either by means of crystallisation, controlled crystallisation, jet milling, or one of the technologies that we master most, spray drying. We keep attentive to these needs and we keep upgrading our toolbox with new hardware and new software. On the hardware side, we recently announced a partnership with Microinnova to embed continuous flow into our offering. On the software side, we have added micellar chemistry, a water-based approach to chemically synthesise active ingredients, addressing sustainability within the broader pharmaceutical industry. How does your manufacturing approach ensure seamless integration from drug substance to drug product both technically and operationally? Hovione has sites located in Europe, Asia, and North America, designed to offer clients a seamless, integrated approach across our network, not only in terms of processes, but also in terms of technologies. These facilities serve clients globally, although naturally some clients favour the local site. In terms of integration, Hovione offers the synthesis of the active ingredient, the manufacturing of intermediates such as amorphous solid dispersions, and the final drug product all in one site. Many companies claim to offer integrated services, but they do this across multiple sites. Hovione does the integration at one site, which reduces hand-offs, streamlines operations and ensures technical alignment. How do technologies such as spray drying and particle engineering, when combined with your chemistry expertise, enhance formulation performance and streamline scale-up timelines? Spray drying has become one of the most versatile technologies in our industry. It addresses challenges that both chemists and formulators face. Chemists are often concerned with problems such as yield, purity or ways of obtaining the right solid-state characteristics of the API, such as polymorphic form. Spray drying can provide a means of isolating materials that are very difficult to isolate by other methods. Examples of compounds that benefit from this include peptides and sugars. On the formulation side, spray drying addresses one of the biggest challenges in the industry: the poor solubility and consequently bioavailability of most of the new drugs. Seventy to ninety per cent of the new drugs in development are poorly soluble. Over the past 20 years, Hovione has developed a platform for making amorphous solid dispersions by spray drying. This platform allows new formulations to be developed with minimum quantities of API and in a short number of few weeks. The technology provides a seamless scale-up from grams to tons, gives clients line-of-sight to commercial production, and saves valuable API at early stages of development. It also allows integration between drug substance and drug product, linking synthesis, intermediate manufacture, and final product in a single site, which is unique in the industry. As molecules and processes become more complex, so too do supply chains. How does Hovione ensure consistency, quality, and regulatory confidence across global operations? Hovione maintains consistency, quality and regulatory confidence through a combination of global assets, standardised platforms and processes, and cross-functional expertise. Our sites are designed to serve global clients while maintaining local responsiveness. We offer high-potency capabilities and advanced particle engineering to address complex molecular challenges. By standardising technologies and processes across sites, Hovione ensures predictable outcomes and adherence to global regulatory requirements. This integrated approach supports reliable supply chains even as molecules and processes grow more complex. With the rise of HPAPIs, novel excipients, and emerging therapeutic modalities, how is Hovione evolving its chemistry and process capabilities to support the next generation of pharmaceutical innovation? We see a trend towards more complex molecules and increasing demand for high-potency compounds. Hovione continues to invest globally, expanding capabilities in high-potency APIs, novel excipients, emerging modalities, and emerging delivery routes such as inhalation or nasal delivery. Chemistry is used as a tool to enable these delivery routes, including synthesis, crystallisation to achieve the right polymorphic form, shape, and size, and optimisation of interactions with excipients. All this is interconnected with our platforms, and amorphous solid dispersions by spray drying, designed to improve bioavailability, the one with the most market credits. Our capabilities bridge drug substance and drug product development and allow us to serve commercial products of different volumes, from small batches to larger scales, all while handling high potency and complex chemistries.   Read the full article at International-Pharma.com  

Article

International Pharmaceutical Industry journal speaks with Márcio Temtem, VP Strategic Business Management at Hovione

Mar 01, 2026